Open AccessMulticentric Reticulohistiocytosis Successfully Treated With Infliximab
Author(s) -
Andrew H. Kalajian,
Jeffrey P. Callen
Publication year - 2008
Publication title -
archives of dermatology
Language(s) - English
Resource type - Journals
eISSN - 1538-3652
pISSN - 0003-987X
DOI - 10.1001/archderm.144.10.1360
Subject(s) - medicine , infliximab , etanercept , methotrexate , prednisone , rheumatoid arthritis , arthritis , adalimumab , leflunomide , constitutional symptoms , dermatology , surgery , tumor necrosis factor alpha , refractory (planetary science) , anakinra , disease , physics , astrobiology
Multicentric reticulohistiocytosis (MR) is a rare multisystem granulomatous disease that frequently results in disfiguring cutaneous deposition, destructive arthritis, and debilitating constitutional symptoms. No consistently effective treatment has been identified. Recently, studies characterizing the cytokine expression profile in MR have prompted therapeutic attempts with tumor necrosis factor (TNF) inhibition. Owing to the rarity of the condition, few such cases have been reported, and controlled studies are unlikely to be performed.